In a major setback for Pharma companies, Bloomberg has confirmed from its sources that U.S. Prosecutors have begun to make headway in the 2 year investigation on generic pharmaceutical companies in relation to suspected price collusion. A clear impact seen in Nifty Pharma which closed 518.30 points or 4.66% down and is currently at levels seen during June on account of Brexit and way back to early . . .